Core Viewpoint - Rosen Law Firm is reminding investors who purchased common stock of Vistagen Therapeutics, Inc. during the specified class period of the upcoming lead plaintiff deadline for a class action lawsuit [1]. Group 1: Class Action Details - Investors who bought Vistagen common stock between April 1, 2024, and December 16, 2025, may be eligible for compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and interested parties must move the Court to serve as lead plaintiff by March 16, 2026 [3]. - Investors can join the class action by visiting the provided link or contacting the law firm directly for more information [7]. Group 2: Legal Representation - Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a proven track record in securities class actions, highlighting its own achievements in this area [4]. - The firm has secured significant settlements for investors, including over $438 million in 2019 alone, and has been recognized for its success in the field [4]. Group 3: Case Background - The lawsuit alleges that Vistagen provided misleading information regarding its drug fasedienol, which is under development for treating social anxiety disorder, while concealing material adverse facts about its Phase 3 PALISADE-3 trial [5][6]. - The defendants' positive assertions about the drug's trial success were contradicted by undisclosed negative information, leading to investor damages when the truth emerged [6].

New York, New York--(Newsfile Corp. - February 4, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Coupang, Inc. (NYSE: CPNG) between August 6, 2025 and December 16, 2025, both dates inclusive (the "Class Period"), of the important February 17, 2026 lead plaintiff deadline in the securities class action first filed by the Firm.SO WHAT: If you purchased Coupang securities during the Class Period you may be entitled to compensation without payment of any out ...

New York, New York--(Newsfile Corp. - February 4, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, announces a class action lawsuit on behalf of purchasers of securities of Beyond Meat, Inc. (NASDAQ: BYND) between February 27, 2025 and November 11, 2025, both dates inclusive (the "Class Period"). A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than March 24, 2026.SO WHAT: If you purchased Beyond Meat securities during th ...

Core Insights - CC Pharma, the European pharmaceutical distribution business of Tilray Brands, has been recognized as a TOP 100 Innovator in Germany, highlighting its innovative strength and contributions to the pharmaceutical sector [1][3]. Company Overview - CC Pharma operates a nationwide distribution network serving over 13,000 pharmacies in Germany, providing access to a wide range of prescription and over-the-counter medicines [2]. - The company is also a key player in the distribution of medical cannabis in Germany, utilizing its established infrastructure and regulatory expertise to enhance patient access in a regulated market [2]. Recognition and Awards - The TOP 100 Innovator Award has been recognizing companies for over 25 years based on their innovative management, forward-looking strategies, and sustainable competitiveness [3]. - CC Pharma's selection as a TOP 100 Innovator reflects its disciplined innovation strategy and commitment to operational excellence in a highly regulated market [4]. Leadership Statements - Rajnish Ohri, President of International at Tilray Brands, emphasized that this recognition underscores CC Pharma's role as a reliable partner in Germany's pharmaceutical ecosystem, focusing on building resilient systems and delivering value [4]. - Mathias Bossen, Managing Director of CC Pharma, expressed pride in the award, highlighting the team's focus on continuous improvement and digitalization, positioning the company as a trusted partner in the pharmaceutical value chain [4]. Market Position - CC Pharma's recognition as a TOP 100 Innovator enhances its reputation as an attractive employer and a significant contributor to Germany's healthcare supply chain [4].

Core Viewpoint - Rosen Law Firm is investigating potential securities claims on behalf of shareholders of Phoenix Education Partners, Inc. due to allegations of materially misleading business information issued to the public [1] Group 1: Legal Actions and Investor Rights - Investors who purchased Phoenix Education securities may be entitled to compensation through a contingency fee arrangement, with no out-of-pocket costs [2] - A class action is being prepared by Rosen Law Firm to seek recovery of investor losses [2] Group 2: Data Breach Incident - A major data breach at the University of Phoenix has affected nearly 3.5 million individuals, with the incident traced back to August when sensitive information was stolen [3] Group 3: Rosen Law Firm's Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved the largest securities class action settlement against a Chinese company and being ranked No. 1 for the number of settlements in 2017 [3] - The firm has recovered hundreds of millions of dollars for investors, including over $438 million in 2019 alone [3] - Founding partner Laurence Rosen was recognized as a Titan of Plaintiffs' Bar by Law360 in 2020, and many attorneys at the firm have received accolades from Lawdragon and Super Lawyers [3]

Core Viewpoint - Rosen Law Firm is investigating potential securities claims on behalf of shareholders of Alvotech due to allegations of materially misleading business information issued by the company [1]. Group 1: Company Information - Alvotech's stock price experienced a significant decline of 34% on November 3, 2025, following the announcement of a complete response letter (CRL) from the U.S. FDA regarding its Biologics License Application (BLA) for AVT05 [3]. - The CRL indicated that certain deficiencies identified during the FDA's pre-license inspection of Alvotech's Reykjavik manufacturing facility must be resolved before the BLA for AVT05 can be approved [3]. Group 2: Legal Actions - Investors who purchased Alvotech securities may be entitled to compensation through a class action lawsuit being prepared by Rosen Law Firm, which operates on a contingency fee basis [2]. - The Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a successful track record in securities class actions, highlighting its own achievements in recovering significant amounts for investors [4].

Core Viewpoint - Rosen Law Firm is investigating potential securities claims on behalf of shareholders of Tandem Diabetes Care, Inc. due to allegations of materially misleading business information issued by the company [1]. Group 1: Company Information - Tandem Diabetes Care, Inc. is facing scrutiny after a press release on August 7, 2025, announced a voluntary medical device correction for select t:slim X2 insulin pumps, which could lead to a discontinuation of insulin delivery due to a speaker-related issue [3]. - Following the announcement, Tandem Diabetes' stock experienced a significant decline of 19.9% on the same day [3]. Group 2: Legal Actions - Investors who purchased Tandem Diabetes securities may be eligible for compensation through a class action lawsuit being prepared by Rosen Law Firm, which operates on a contingency fee basis [2]. - The firm emphasizes the importance of selecting qualified legal counsel with a proven track record in securities class actions, highlighting its own success in recovering substantial amounts for investors [4]. Group 3: Firm's Credentials - Rosen Law Firm has achieved notable recognition, including the largest securities class action settlement against a Chinese company and being ranked No. 1 for securities class action settlements in 2017 [4]. - The firm has consistently ranked in the top 4 for securities class action settlements since 2013 and has recovered hundreds of millions of dollars for investors, including over $438 million in 2019 alone [4].

New York, New York--(Newsfile Corp. - February 2, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Bath & Body Works, Inc. (NYSE: BBWI) between June 4, 2024 and November 19, 2025, both dates inclusive (the "Class Period"), of the important March 16, 2026 lead plaintiff deadline.SO WHAT: If you purchased Bath & Body Works securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a conti ...

Core Viewpoint - Rosen Law Firm is investigating potential securities claims on behalf of shareholders of Simulations Plus, Inc. due to allegations of materially misleading business information issued by the company [1]. Group 1: Company Performance - Simulations Plus reported sales of $20.4 million for the third quarter of 2025, which is a 10% year-over-year increase but fell short of the consensus estimate of $20.9 million [3]. - The company had previously released preliminary third-quarter sales figures in June, which were already lower than expectations at $19 million to $20 million, compared to a consensus of $22.78 million [3]. - Following the earnings report, Simulations Plus stock experienced a significant decline of 25.75% on July 15, 2025 [3]. Group 2: Legal Action - Investors who purchased Simulations Plus securities may be entitled to compensation through a class action lawsuit being prepared by Rosen Law Firm, with no out-of-pocket fees or costs due to a contingency fee arrangement [2]. - Interested investors can join the prospective class action by submitting a form or contacting the law firm directly [2]. Group 3: Rosen Law Firm's Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved the largest securities class action settlement against a Chinese company and being ranked No. 1 for the number of settlements in 2017 [4]. - The firm has recovered hundreds of millions of dollars for investors, securing over $438 million in 2019 alone [4]. - Founding partner Laurence Rosen was recognized as a Titan of Plaintiffs' Bar by Law360 in 2020, and many attorneys at the firm have received accolades from Lawdragon and Super Lawyers [4].

Core Viewpoint - Rosen Law Firm has initiated a class action lawsuit on behalf of purchasers of Oracle Corporation's senior notes, alleging that the Offering Documents contained misleading statements regarding Oracle's need for additional debt to build AI infrastructure, which affected the creditworthiness of the bonds [1][4]. Group 1: Lawsuit Details - The class action lawsuit claims that Oracle failed to disclose its requirement for significant additional debt at the time of the Offering, which ultimately led to damages for investors when the true situation was revealed [4]. - Investors who purchased Oracle senior notes may be eligible for compensation without incurring out-of-pocket fees through a contingency fee arrangement [2]. Group 2: Rosen Law Firm's Credentials - Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a proven track record in securities class actions, highlighting its own success in recovering hundreds of millions for investors [3]. - The firm has been recognized for its achievements, including being ranked No. 1 for securities class action settlements in 2017 and securing over $438 million for investors in 2019 [3].